PMC:7205724 / 305-526
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
5 | 26-34 | Disease | denotes | COVID-19 | MESH:C000657245 |
7 | 109-117 | Disease | denotes | COVID-19 | MESH:C000657245 |
10 | 122-125 | Gene | denotes | IL6 | Gene:3569 |
11 | 194-202 | Disease | denotes | COVID-19 | MESH:C000657245 |
20 | 207-218 | Chemical | denotes | Tocilizumab | MESH:C502936 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 26-34 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 109-117 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 194-202 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T5 | 89-104 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T2 | 165-175 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | viral load | http://purl.bioontology.org/ontology/MEDDRA/10062178 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T4 | 89-104 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T2 | 26-34 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T3 | 109-117 | Species | denotes | COVID-19 | NCBItxid:2697049 |
T4 | 194-202 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 36-118 | Sentence | denotes | • No controlled clinical trials exist on the use of corticosteroids for COVID-19. |
T8 | 119-203 | Sentence | denotes | • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
5 | 26-34 | Disease | denotes | COVID-19 | MESH:C000657245 |
7 | 109-117 | Disease | denotes | COVID-19 | MESH:C000657245 |
10 | 122-125 | Gene | denotes | IL6 | Gene:3569 |
11 | 194-202 | Disease | denotes | COVID-19 | MESH:C000657245 |
20 | 207-218 | Chemical | denotes | Tocilizumab | MESH:C502936 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T1 | 122-125 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T43 | 1-11 | VB | denotes | accelerate |
T44 | 12-20 | NN | denotes | recovery |
T45 | 21-25 | IN | denotes | from |
T46 | 26-34 | NN | denotes | COVID-19 |
T47 | 36-37 | PDT | denotes | • |
T48 | 39-41 | DT | denotes | No |
T49 | 42-52 | VBN | denotes | controlled |
T50 | 53-61 | JJ | denotes | clinical |
T51 | 62-68 | NNS | denotes | trials |
T52 | 69-74 | VBP | denotes | exist |
T53 | 75-77 | IN | denotes | on |
T54 | 78-81 | DT | denotes | the |
T55 | 82-85 | NN | denotes | use |
T56 | 86-88 | IN | denotes | of |
T57 | 89-104 | NNS | denotes | corticosteroids |
T58 | 105-108 | IN | denotes | for |
T59 | 109-117 | NN | denotes | COVID-19 |
T60 | 119-120 | LS | denotes | • |
T61 | 122-125 | NN | denotes | IL6 |
T62 | 126-136 | VBZ | denotes | correlates |
T63 | 137-141 | IN | denotes | with |
T64 | 142-150 | NN | denotes | severity |
T65 | 150-151 | -COMMA- | denotes | , |
T66 | 152-163 | NN | denotes | criticality |
T67 | 163-164 | -COMMA- | denotes | , |
T68 | 165-170 | JJ | denotes | viral |
T69 | 171-175 | NN | denotes | load |
T70 | 175-176 | -COMMA- | denotes | , |
T71 | 177-180 | CC | denotes | and |
T72 | 181-190 | NN | denotes | prognosis |
T73 | 191-193 | IN | denotes | of |
T74 | 194-202 | NN | denotes | COVID-19 |
T75 | 204-205 | IN | denotes | • |
T76 | 207-218 | NNP | denotes | Tocilizumab |
T77 | 218-219 | -COMMA- | denotes | , |
R40 | T44 | T43 | arg2Of | recovery,accelerate |
R41 | T44 | T45 | arg1Of | recovery,from |
R42 | T46 | T45 | arg2Of | COVID-19,from |
R43 | T51 | T47 | arg1Of | trials,• |
R44 | T51 | T48 | arg1Of | trials,No |
R45 | T51 | T49 | arg2Of | trials,controlled |
R46 | T51 | T50 | arg1Of | trials,clinical |
R47 | T51 | T52 | arg1Of | trials,exist |
R48 | T52 | T53 | arg1Of | exist,on |
R49 | T55 | T53 | arg2Of | use,on |
R50 | T55 | T54 | arg1Of | use,the |
R51 | T55 | T56 | arg1Of | use,of |
R52 | T57 | T56 | arg2Of | corticosteroids,of |
R53 | T55 | T58 | arg1Of | use,for |
R54 | T59 | T58 | arg2Of | COVID-19,for |
R55 | T62 | T60 | arg1Of | correlates,• |
R56 | T61 | T62 | arg1Of | IL6,correlates |
R57 | T62 | T63 | arg1Of | correlates,with |
R58 | T71 | T63 | arg2Of | and,with |
R59 | T64 | T65 | arg1Of | severity,"," |
R60 | T66 | T65 | arg2Of | criticality,"," |
R61 | T65 | T67 | arg1Of | ",","," |
R62 | T69 | T67 | arg2Of | load,"," |
R63 | T69 | T68 | arg1Of | load,viral |
R64 | T71 | T70 | arg1Of | and,"," |
R65 | T67 | T71 | arg1Of | ",",and |
R66 | T72 | T71 | arg2Of | prognosis,and |
R67 | T72 | T73 | arg1Of | prognosis,of |
R68 | T74 | T73 | arg2Of | COVID-19,of |
R70 | T76 | T77 | arg1Of | Tocilizumab,"," |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T2 | 26-34 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 109-117 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 194-202 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 36-118 | Sentence | denotes | • No controlled clinical trials exist on the use of corticosteroids for COVID-19. |
T8 | 119-203 | Sentence | denotes | • IL6 correlates with severity, criticality, viral load, and prognosis of COVID-19. |